Photocure ASA to Acquire Vesica Health Inc., Strengthening Leadership in Bladder Cancer Diagnostics

Photocure ASA, a prominent player in bladder cancer diagnostics, has finalized its acquisition of Vesica Health Inc. for a total transaction value of $30.5 million. The deal, which closed on June 4, 2026, comprises both cash and stock components, with a net consideration of approximately $28.5 million after factoring in the cash reserves held by Vesica Health. At the close, Photocure will pay $13.75 million, consisting of $11 million in cash and $2.75 million in Photocure equity. Additional milestone payments are contingent on achieving Medicare reimbursement benchmarks.

The acquisition of Vesica Health is strategically significant for Photocure, as it enhances the company’s portfolio with the AssureMDx test, a urine-based molecular diagnostic tool designed for the early detection of bladder cancer. AssureMDx utilizes a multi-omic approach, integrating six biomarkers to aid in the risk stratification of patients presenting with hematuria, a condition affecting approximately seven million individuals in the U.S. annually. The test has demonstrated impressive clinical validation, achieving a sensitivity of 96% and a negative predictive value of 99.7%, making it a valuable addition to Photocure's existing diagnostic offerings.

Photocure's acquisition aligns with its broader strategy to expand its footprint in the bladder cancer care continuum. By integrating Vesica Health's capabilities, Photocure aims to leverage its established commercial infrastructure and relationships within the urology sector to accelerate the commercialization of AssureMDx. This move not only enhances Photocure's diagnostic technology portfolio but also positions the company to capitalize on the growing market for hematuria evaluation, which is increasingly recognized as a critical area for early bladder cancer detection.

The financial structure of the deal includes future milestone payments based on Vesica Health's success in securing Medicare reimbursement. These payments include $5.5 million in cash and $5.5 million in Photocure equity, contingent on meeting specific regulatory milestones by the end of 2029. This performance-based component reflects the importance of reimbursement pathways in the healthcare sector, particularly for innovative diagnostic tests that require validation and adoption in clinical practice.

In summary, the acquisition of Vesica Health by Photocure ASA represents a strategic enhancement of its bladder cancer diagnostics capabilities, particularly through the introduction of the AssureMDx test. As the healthcare market increasingly prioritizes early detection and noninvasive diagnostic solutions, this transaction positions Photocure to drive growth and improve patient outcomes in the bladder cancer space. The successful integration of Vesica Health's technology could also set a precedent for future collaborations and acquisitions in the rapidly evolving diagnostics sector.